Related references
Note: Only part of the references are listed.Amyloid-β-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease
Margarita C. Dinamarca et al.
MOLECULAR NEURODEGENERATION (2010)
Altered Levels of Acetylcholinesterase in Alzheimer Plasma
Maria-Salud Garcia-Ayllon et al.
PLOS ONE (2010)
Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients
Agneta Nordberg et al.
CURRENT ALZHEIMER RESEARCH (2009)
Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine
Iti Bansal et al.
JOURNAL OF APPLIED TOXICOLOGY (2009)
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine
T. Darreh-Shori et al.
NEUROBIOLOGY OF AGING (2008)
Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease
Maria-Salud Garcia-Ayllon et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Kaj Blennow et al.
NEUROSCIENCE LETTERS (2007)
Sensitivity of butyrylcholinesterase knockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission
Ellen G. Duysen et al.
TOXICOLOGY (2007)
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment
T. Darreh-Shori et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
H Kaduszkiewicz et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation
C Holmes et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex
T Rees et al.
NEUROBIOLOGY OF AGING (2003)
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease
J Sáez-Valero et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
Clinical pharmacokinetics of galantamine
MR Farlow
CLINICAL PHARMACOKINETICS (2003)
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors
L Parnetti et al.
NEUROLOGICAL SCIENCES (2002)
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
T Darreh-Shori et al.
NEUROLOGY (2002)
Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection
N Yasui-Furukori et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2002)
Cerebrospinal fluid τ and β-amyloid(I-42) in dementia disorders
E Vanmechelen et al.
MECHANISMS OF AGEING AND DEVELOPMENT (2001)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
B Winblad et al.
NEUROLOGY (2001)
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
P Davidsson et al.
NEUROSCIENCE LETTERS (2001)
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro
H Ogura et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2000)
Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
A Maelicke et al.
BEHAVIOURAL BRAIN RESEARCH (2000)
Share Paper
